Profound Medical Corp. (NASDAQ:PROF) Shares Purchased by FIL Ltd

FIL Ltd boosted its position in shares of Profound Medical Corp. (NASDAQ:PROF - Free Report) by 16.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,795,000 shares of the company's stock after buying an additional 260,000 shares during the period. FIL Ltd owned 5.98% of Profound Medical worth $13,486,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Gagnon Securities LLC grew its holdings in shares of Profound Medical by 12.6% during the fourth quarter. Gagnon Securities LLC now owns 1,652,531 shares of the company's stock worth $12,411,000 after buying an additional 185,284 shares during the last quarter. Gagnon Advisors LLC raised its holdings in Profound Medical by 20.0% during the fourth quarter. Gagnon Advisors LLC now owns 896,671 shares of the company's stock worth $6,734,000 after purchasing an additional 149,445 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Profound Medical in the fourth quarter valued at about $6,577,000. Royce & Associates LP increased its position in Profound Medical by 34.3% during the 4th quarter. Royce & Associates LP now owns 764,799 shares of the company's stock worth $5,746,000 after purchasing an additional 195,501 shares during the period. Finally, Rosalind Advisors Inc. raised its stake in shares of Profound Medical by 42.4% during the 4th quarter. Rosalind Advisors Inc. now owns 692,185 shares of the company's stock worth $5,198,000 after buying an additional 206,212 shares in the last quarter. 47.86% of the stock is owned by institutional investors and hedge funds.

Profound Medical Price Performance

PROF stock traded up $0.01 on Thursday, reaching $4.73. 9,817 shares of the company's stock were exchanged, compared to its average volume of 57,302. The stock has a fifty day moving average of $6.26 and a 200-day moving average of $7.08. The firm has a market cap of $142.09 million, a PE ratio of -3.53 and a beta of 0.68. The company has a quick ratio of 5.16, a current ratio of 6.12 and a debt-to-equity ratio of 0.11. Profound Medical Corp. has a twelve month low of $3.90 and a twelve month high of $11.42.

Profound Medical (NASDAQ:PROF - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.11. The company had revenue of $4.18 million for the quarter, compared to analyst estimates of $5.92 million. Profound Medical had a negative net margin of 349.41% and a negative return on equity of 85.22%. As a group, equities analysts predict that Profound Medical Corp. will post -1.12 EPS for the current fiscal year.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.